

## Cephapirin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	420300-00019	Date of first issue: 28.01.2016

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Cephapirin Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-  
stance/Mixture : Veterinary product

Recommended restrictions  
on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
20 Spartan Road  
1619 Spartan, South Africa

Telephone : +27119239300

E-mail address of person  
responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

+1-908-423-6000

---

### SECTION 2: Hazards identification


#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Respiratory sensitisation, Category 1 H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms : 

Signal word : Danger

Hazard statements : H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Precautionary statements : **Response:**  
P304 + P340 IF INHALED: Remove person to fresh air and

## Cephapirin Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 420300-00019      Date of last issue: 04.04.2023  
Date of first issue: 28.01.2016

keep comfortable for breathing.  
P342 + P311    If experiencing respiratory symptoms: Call a  
POISON CENTER/ doctor.

Hazardous components which must be listed on the label:  
Cefapirin

**2.3 Other hazards**

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

**SECTION 3: Composition/information on ingredients****3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Cefapirin	21593-23-7 244-466-5	Resp. Sens. 1A; H334	>= 1 - < 10

For explanation of abbreviations see section 16.

**SECTION 4: First aid measures****4.1 Description of first aid measures**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
If not breathing, give artificial respiration.  
If breathing is difficult, give oxygen.  
Get medical attention.
- In case of skin contact : Wash with water and soap as a precaution.  
Get medical attention if symptoms occur.
- In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.

## Cephapirin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	420300-00019	Date of first issue: 28.01.2016

---

Rinse mouth thoroughly with water.

### 4.2 Most important symptoms and effects, both acute and delayed

Risks : May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

---

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

---

## Cephapirin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	420300-00019	Date of first issue: 28.01.2016

---

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

---

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Avoid breathing mist or vapours.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.  
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures,

## Cephapirin Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 420300-00019      Date of last issue: 04.04.2023  
 Date of first issue: 28.01.2016

industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**7.2 Conditions for safe storage, including any incompatibilities**

Requirements for storage areas and containers : Keep in properly labelled containers. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:  
 Strong oxidizing agents  
 Gases

**7.3 Specific end use(s)**

Specific use(s) : No data available

**SECTION 8: Exposure controls/personal protection****8.1 Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cefapirin	21593-23-7	TWA	0.4 mg/m <sup>3</sup> (OEB 2)	Internal
Further information: RSEN				

**Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:**

Substance name	End Use	Exposure routes	Potential health effects	Value
Glycerides, mixed decanoyl and octanoyl	Workers	Inhalation	Long-term systemic effects	177,79 mg/m <sup>3</sup>
	Workers	Skin contact	Long-term systemic effects	25,21 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	43,84 mg/m <sup>3</sup>
	Consumers	Skin contact	Long-term systemic effects	12,61 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	12,61 mg/kg bw/day

**Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:**

Substance name	Environmental Compartment	Value
Glycerides, mixed decanoyl and octanoyl	Oral (Secondary Poisoning)	0,03 mg/kg food

**8.2 Exposure controls****Engineering measures**

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Laboratory operations do not require special containment.

## Cephapirin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	420300-00019	Date of first issue: 28.01.2016

---

**Personal protective equipment**

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection	:	
Material	:	Chemical-resistant gloves
Skin and body protection	:	Work uniform or laboratory coat.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Combined particulates and organic vapour type (A-P)

---

**SECTION 9: Physical and chemical properties****9.1 Information on basic physical and chemical properties**

Appearance	:	liquid
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available

## Cephapirin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	420300-00019	Date of first issue: 28.01.2016

---

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

### 9.2 Other information

Flammability (liquids) : No data available

Molecular weight : No data available

Particle size : No data available

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : None known.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

Information on likely routes of exposure :  
Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

**Cefapirin:**

**Cephapirin Formulation**

Version 4.1      Revision Date: 30.09.2023      SDS Number: 420300-00019      Date of last issue: 04.04.2023  
Date of first issue: 28.01.2016

---

Acute oral toxicity : LD50 (Mouse): 26.000 mg/kg

Acute toxicity (other routes of administration) : LD50 (Mouse): > 7.600 mg/kg  
Application Route: Intraperitoneal

LD50 (Rat): 7.800 mg/kg  
Application Route: Intraperitoneal

**Skin corrosion/irritation**

Not classified based on available information.

**Serious eye damage/eye irritation**

Not classified based on available information.

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**Components:****Cefapirin:**

Assessment : Probability or evidence of high respiratory sensitisation rate in humans

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Cefapirin:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Reproductive toxicity**

Not classified based on available information.

**Components:****Cefapirin:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Intraperitoneal injection  
Fertility: LOAEL: > 500 mg/kg body weight  
Result: No effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intraperitoneal injection



## Cephapirin Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 420300-00019      Date of last issue: 04.04.2023  
Date of first issue: 28.01.2016

---

Developmental Toxicity: LOAEL: > 200 mg/kg body weight

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

Not classified based on available information.

### Repeated dose toxicity

#### Components:

##### Cefapirin:

Species : Rat  
LOAEL :  $\geq$  200 mg/kg  
Application Route : Intraperitoneal  
Target Organs : Blood  
Remarks : anemia

Species : Dog  
LOAEL : 20 mg/kg  
Application Route : Oral  
Exposure time : 4 Months  
Target Organs : Gastrointestinal tract

Species : Dog  
LOAEL : 100 mg/kg  
Application Route : Intramuscular  
Exposure time : 10 Months  
Target Organs : Blood, Gastrointestinal tract  
Remarks : anemia

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

##### Cefapirin:

Ingestion : Symptoms: Nausea, Vomiting, Abdominal pain, Diarrhoea, vaginitis, colitis, anorexia, Rash, anaphylaxis

---

## SECTION 12: Ecological information

### 12.1 Toxicity

No data available

### 12.2 Persistence and degradability

No data available

### 12.3 Bioaccumulative potential

No data available

## Cephapirin Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 420300-00019      Date of last issue: 04.04.2023  
Date of first issue: 28.01.2016

---

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

**Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Other adverse effects

**Product:**

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

## SECTION 14: Transport information

### 14.1 UN number

ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

### 14.2 UN proper shipping name

ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good

## Cephapirin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	420300-00019	Date of first issue: 28.01.2016

---

IATA : Not regulated as a dangerous good

**14.3 Transport hazard class(es)**

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

**14.4 Packing group**

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA (Cargo) : Not regulated as a dangerous good

IATA (Passenger) : Not regulated as a dangerous good

**14.5 Environmental hazards**

Not regulated as a dangerous good

**14.6 Special precautions for user**

Not applicable

**14.7 Transport in bulk according to Annex II of Marpol and the IBC Code**

Remarks : Not applicable for product as supplied.

---

**SECTION 15: Regulatory information****15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

**15.2 Chemical safety assessment**

A Chemical Safety Assessment has not been carried out.

---

**SECTION 16: Other information**

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

**Cephapirin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	420300-00019	Date of first issue: 28.01.2016

---

**Full text of H-Statements**

H334 : May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**Full text of other abbreviations**

Resp. Sens. : Respiratory sensitisation

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

**Classification of the mixture:**

Resp. Sens. 1 H334

**Classification procedure:**

Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS mate-

## Cephapirin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	420300-00019	Date of first issue: 28.01.2016

---

Material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN